<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30349477</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1663-9812</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in pharmacology</Title>                <ISOAbbreviation>Front Pharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Repurposing of Bromocriptine for Cancer Therapy.</ArticleTitle>            <Pagination>                <MedlinePgn>1030</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2018.01030</ELocationID>            <Abstract>                <AbstractText>Bromocriptine is an ergot alkaloid and dopamine D<sub>2</sub> receptor agonist used to treat Parkinson's disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. We found that bromocriptine was cytotoxic towards drug-sensitive CCRF-CEM, multidrug-resistant CEM/ADR5000 leukemic cells as well as wild-type or multidrug-resistant ABCB5-transfected HEK293 cell lines, but not sensitive or BCRP-transfected multidrug-resistant MDA-MB-231 breast cancer cells. Bromocriptine strongly bound to NF-κB pathway proteins as shown by molecular docking and interacted more strongly with DNA-bound NF-κB than free NF-κB, indicating that bromocriptine may inhibit NF-κB binding to DNA. Furthermore, bromocriptine decreased NF-κB activity by a SEAP-driven NF-κB reporter cell assay. The expression of MDR-conferring ABC-transporters (ABCB1, ABCB5, ABCC1, and ABCG2) and other resistance-mediating factors (EGFR, mutated TP53, and IκB) did not correlate with cellular response to bromocriptine in a panel of 60 NCI cell lines. There was no correlation between cellular response to bromocriptine and anticancer drugs usually involved in MDR (e.g., anthracyclines, <i>Vinca</i> alkaloids, taxanes, epipodophyllotoxins, and others). COMPARE analysis of microarray-based mRNA expression in these cell lines revealed that genes from various functional groups such as ribosomal proteins, transcription, translation, DNA repair, DNA damage, protein folding, mitochondrial respiratory chain, and chemokines correlated with cellular response to bromocriptine. Our results indicate that bromocriptine inhibited drug-resistant tumor cells with different resistance mechanisms in a hormone-independent manner. As refractory and otherwise drug-resistant tumors represent a major challenge to successful cancer chemotherapy, bromocriptine may be considered for repurposing in cancer therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Seo</LastName>                    <ForeName>Ean-Jeong</ForeName>                    <Initials>EJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sugimoto</LastName>                    <ForeName>Yoshikazu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Greten</LastName>                    <ForeName>Henry Johannes</ForeName>                    <Initials>HJ</Initials>                    <AffiliationInfo>                        <Affiliation>Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, Portugal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Efferth</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Pharmacol</MedlineTA>            <NlmUniqueID>101548923</NlmUniqueID>            <ISSNLinking>1663-9812</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Phytomedicine. 2011 Aug 15;18(11):959-69</RefSource>                <PMID Version="1">21831619</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Pharmacol. 2003 Aug;64(2):382-94</RefSource>                <PMID Version="1">12869643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetol Metab Syndr. 2014 Sep 25;6:104</RefSource>                <PMID Version="1">25937836</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2012 Feb 24;418(4):736-41</RefSource>                <PMID Version="1">22306008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Surg Oncol. 1999 Nov;8(3):143-53</RefSource>                <PMID Version="1">11113665</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1990 Nov 1;50(21):6793-9</RefSource>                <PMID Version="1">1698543</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2016 Sep 27;5(1):1666</RefSource>                <PMID Version="1">27730025</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2006 Aug;28(8):1065-1078</RefSource>                <PMID Version="1">16982285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Org Biomol Chem. 2010 Jul 21;8(14):3149-56</RefSource>                <PMID Version="1">20485753</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biopharm Stat. 2007;17(3):461-80</RefSource>                <PMID Version="1">17479394</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurochem. 1994 Mar;62(3):1034-8</RefSource>                <PMID Version="1">8113789</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1997 Jan 17;275(5298):343-9</RefSource>                <PMID Version="1">8994024</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2008 Jan 18;259(1):111-8</RefSource>                <PMID Version="1">18006147</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Neuropharmacol. 2001 Sep-Oct;24(5):247-53</RefSource>                <PMID Version="1">11586109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2001 Feb;107(3):241-6</RefSource>                <PMID Version="1">11160144</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Jpn J Cancer Res. 2002 Feb;93(2):209-15</RefSource>                <PMID Version="1">11856485</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2017 Jun;39(6):1010428317706919</RefSource>                <PMID Version="1">28653902</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Jan 15;68(2):415-24</RefSource>                <PMID Version="1">18199535</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes. 2009 Apr;58(4):773-95</RefSource>                <PMID Version="1">19336687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2002 Mar 7;21(11):1759-67</RefSource>                <PMID Version="1">11896607</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Pract. 2010 Jan-Feb;16(1):42-6</RefSource>                <PMID Version="1">19703803</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2012 Jun 8;149(6):1284-97</RefSource>                <PMID Version="1">22632761</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Chem Inf Model. 2013 Sep 23;53(9):2402-8</RefSource>                <PMID Version="1">23906322</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Biochem. 1993;62:385-427</RefSource>                <PMID Version="1">8102521</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Arch. 2013;67(3):181-4</RefSource>                <PMID Version="1">23848038</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Protoc. 2006;1(5):2315-9</RefSource>                <PMID Version="1">17406473</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Immunol. 2009;29(3):241-54</RefSource>                <PMID Version="1">19538137</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2004 Jul;3(7):803-12</RefSource>                <PMID Version="1">15252141</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Experientia. 1992 Mar 15;48(3):248-53</RefSource>                <PMID Version="1">1547854</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Endocrinol Invest. 1988 Jan;11(1):47-51</RefSource>                <PMID Version="1">3361075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1997 Oct 15;89(20):1505-15</RefSource>                <PMID Version="1">9337347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Physiol. 2008;70:513-35</RefSource>                <PMID Version="1">17988209</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70</RefSource>                <PMID Version="1">9861027</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 1998 Jul-Aug;5(4):893-6</RefSource>                <PMID Version="1">9625840</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Phytomedicine. 2016 Mar 15;23(3):293-306</RefSource>                <PMID Version="1">26969383</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Complement Altern Med. 2016 Aug 02;16:267</RefSource>                <PMID Version="1">27484842</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73</RefSource>                <PMID Version="1">16886971</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacol Rep. 2005 Nov-Dec;57(6):701-12</RefSource>                <PMID Version="1">16382188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Res. 2010 Dec 10;1364:198-215</RefSource>                <PMID Version="1">20869351</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 2000 Mar;24(3):236-44</RefSource>                <PMID Version="1">10700175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2004 Aug;3(8):673-83</RefSource>                <PMID Version="1">15286734</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 1996 Jun;19(6):667-70</RefSource>                <PMID Version="1">8725871</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Med Res Opin. 1986;10(1):25-51</RefSource>                <PMID Version="1">3516579</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nat Prod. 2015 Apr 24;78(4):762-75</RefSource>                <PMID Version="1">25713926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharmacol Exp Ther. 2002 Nov;303(2):791-804</RefSource>                <PMID Version="1">12388666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2000 Aug;23(8):1154-61</RefSource>                <PMID Version="1">10937514</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Pharmacol. 2018 Feb 27;9:143</RefSource>                <PMID Version="1">29535630</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2017 May 5;12(5):e0176910</RefSource>                <PMID Version="1">28475602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Res. 2011 Jan;21(1):103-15</RefSource>                <PMID Version="1">21187859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuro Endocrinol Lett. 2000;21(5):405-408</RefSource>                <PMID Version="1">11452236</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mark Access Health Policy. 2013 Aug 06;1:null</RefSource>                <PMID Version="1">27226826</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2001 May 1;21(9):3207-14</RefSource>                <PMID Version="1">11312305</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2008 Jul;7(7):1827-35</RefSource>                <PMID Version="1">18644995</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Biochem. 2000 Sep;267(17):5421-6</RefSource>                <PMID Version="1">10951200</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Leukemia. 2010 Apr;24(4):806-12</RefSource>                <PMID Version="1">20130599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2009 Jul 15;125(2):308-17</RefSource>                <PMID Version="1">19378338</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Feb 9;7(6):6609-19</RefSource>                <PMID Version="1">26735888</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Reprod Med. 1999 Dec;44(12 Suppl):1105-10</RefSource>                <PMID Version="1">10649819</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2008 Oct 1;105(2):554-61</RefSource>                <PMID Version="1">18636537</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 1988 Mar 19;1(8586):609-10</RefSource>                <PMID Version="1">2894547</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Invest New Drugs. 2014 Aug;32(4):618-25</RefSource>                <PMID Version="1">24748336</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Mol Med. 2017 Apr;9(4):498-507</RefSource>                <PMID Version="1">28264936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>FASEB J. 1998 Jul;12(10):905-12</RefSource>                <PMID Version="1">9657530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93</RefSource>                <PMID Version="1">17520257</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2008 Feb 8;132(3):344-62</RefSource>                <PMID Version="1">18267068</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Cancer Res. 1963;7:235-50</RefSource>                <PMID Version="1">14153767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nutr Biochem. 2015 Jan;26(1):44-56</RefSource>                <PMID Version="1">25459885</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(5):e35584</RefSource>                <PMID Version="1">22590507</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">bromocriptine</Keyword>            <Keyword MajorTopicYN="N">drug repurposing</Keyword>            <Keyword MajorTopicYN="N">ergot alkaloids</Keyword>            <Keyword MajorTopicYN="N">neoplasms</Keyword>            <Keyword MajorTopicYN="N">pharmacogenomics</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30349477</ArticleId>            <ArticleId IdType="doi">10.3389/fphar.2018.01030</ArticleId>            <ArticleId IdType="pmc">PMC6187981</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>